Medpace Holdings, Inc. (MEDP) Current Ratio: 0.74
Is Medpace Holdings, Inc.’s current ratio high or low?
Medpace Holdings, Inc.'s current ratio of 0.74 is 12% below its 5-year average of 0.84, around the middle of its 5-year range (0.42–1.24).
As of Wednesday, June 17, 2026. 11.38% below its 12-month average of 0.83.
MEDP Current Ratio Chart
MEDP Average Current Ratio Chart
MEDP Current vs Average Current Ratio Chart
MEDP Current Ratio Metrics
CURRENT RATIO
0.74
CURRENT RATIO AVG TTM
0.83
CURRENT RATIO AVG 3Y
0.68
CURRENT RATIO AVG 5Y
0.84
CURRENT RATIO AVG 10Y
0.80
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-11.38%
CURRENT VS 3Y AVG
+8.42%
CURRENT VS 5Y AVG
-12.08%
CURRENT VS 10Y AVG
-7.81%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' Current Ratio
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.05B | 0.74 | 0.83 | 0.68 | 0.84 |
| Solventum Corporation (SOLV)vs › | $12.91B | 1.23 | 1.21 | 1.40 | 1.43 |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 1.89 | 1.90 | 1.69 | 1.67 |
| DaVita Inc. (DVA)vs › | $13.52B | 1.29 | 1.27 | 1.23 | 1.26 |
| Align Technology, Inc. (ALGN)vs › | $12.43B | 1.36 | 1.29 | 1.26 | 1.29 |
| Revvity, Inc. (RVTY)vs › | $10.91B | 1.68 | 2.64 | 2.37 | 2.14 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.68 | 0.66 | 0.70 | 0.70 |
| Baxter International Inc. (BAX)vs › | $10.19B | 2.31 | 1.83 | 1.71 | 1.91 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 3.75 | 3.72 | 3.76 | 3.20 |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | 1.29 | 1.35 | 1.39 | 1.37 |
Liquidity Analysis
Current Ratio
0.74
Quick Ratio
0.74
Medpace Holdings, Inc. Current Ratio Formula & Definition
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Current Ratio FAQ
- What is the current ratio for Medpace Holdings, Inc. (MEDP)?
- The current ratio for MEDP stock is 0.74.
- Is Medpace Holdings, Inc.'s current ratio high or low?
- Medpace Holdings, Inc.'s current ratio of 0.74 is 12% below its 5-year average of 0.84, around the middle of its 5-year range (0.42–1.24).
- What is the TTM average current ratio for Medpace Holdings, Inc. (MEDP)?
- The TTM average current ratio for MEDP stock is 0.83.
- What is the 3Y average current ratio for Medpace Holdings, Inc. (MEDP)?
- The 3Y average current ratio for MEDP stock is 0.68.
- What is the 5Y average current ratio for Medpace Holdings, Inc. (MEDP)?
- The 5Y average current ratio for MEDP stock is 0.84.
- What is the 10Y average current ratio for Medpace Holdings, Inc. (MEDP)?
- The 10Y average current ratio for MEDP stock is 0.80.
Medpace Holdings, Inc. Current Ratio History
| DATE | CURRENT RATIO |
|---|---|
| 2025-12-31 | 0.74 |
| 2024-12-31 | 0.93 |
| 2023-12-31 | 0.64 |
| 2022-12-31 | 0.42 |
| 2021-12-31 | 1.24 |
| 2020-12-31 | 1.08 |
| 2019-12-31 | 0.92 |
| 2018-12-31 | 0.69 |
| 2017-12-31 | 0.67 |
| 2016-12-31 | 0.79 |
| 2015-12-31 | 0.71 |
| 2014-12-31 | 1.00 |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle